Kaken Pharmaceutical Co., Ltd. (TYO:4521)

Kaken Pharmaceutical Income Statement

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	82,019	94,035	72,044	72,984	76,034	74,979
Revenue Growth (YoY)	-5.99%	30.52%	-1.29%	-4.01%	1.41%	-15.97%
Cost of Revenue	36,009	35,502	33,505	33,428	34,458	34,073
Gross Profit	46,010	58,533	38,539	39,556	41,576	40,906
Selling, General & Admin	19,656	18,501	16,165	15,476	15,833	16,155
Research & Development	24,424	18,725	12,543	15,789	8,420	6,736
Operating Expenses	44,351	37,497	29,025	31,556	24,511	23,118
Operating Income	1,659	21,036	9,514	8,000	17,065	17,788
Interest Expense	-37	-28	-17	-17	-17	-17
Interest & Investment Income	747	613	479	438	396	393
Currency Exchange Gain (Loss)	-302	-370	-59	-	-31	-12
Other Non Operating Income (Expenses)	-5	28	32	306	129	69
EBT Excluding Unusual Items	2,062	21,279	9,949	8,727	17,542	18,221
Gain (Loss) on Sale of Investments	1,119	-287	13	1	1	115
Gain (Loss) on Sale of Assets	-	-	-	1	195	379
Asset Writedown	-1,579	-1,556	-167	-1,911	-3,091	-54
Other Unusual Items	-6	-1	-	-1	-762	-4
Pretax Income	1,596	19,435	9,795	6,817	13,885	18,657
Income Tax Expense	945	5,490	1,770	1,377	4,336	5,252
Net Income	651	13,945	8,025	5,440	9,549	13,405
Net Income to Common	651	13,945	8,025	5,440	9,549	13,405
Net Income Growth	-96.43%	73.77%	47.52%	-43.03%	-28.77%	-30.80%
Shares Outstanding (Basic)	38	38	38	38	38	39
Shares Outstanding (Diluted)	38	38	38	38	38	39
Shares Change (YoY)	0.88%	1.13%	0.44%	-1.07%	-1.59%	-1.41%
EPS (Basic)	17.04	365.42	212.66	144.79	251.44	347.37
EPS (Diluted)	17.04	365.42	212.66	144.79	251.44	347.37
EPS Growth	-96.46%	71.83%	46.87%	-42.41%	-27.62%	-29.81%
Free Cash Flow	-5,256	25,642	716	7,266	10,350	12,407
Free Cash Flow Per Share	-137.58	671.92	18.97	193.39	272.53	321.51
Dividend Per Share	170.000	150.000	150.000	150.000	150.000	150.000
Dividend Growth	13.33%	-	-	-	-	-
Gross Margin	56.10%	62.25%	53.49%	54.20%	54.68%	54.56%
Operating Margin	2.02%	22.37%	13.21%	10.96%	22.44%	23.72%
Profit Margin	0.79%	14.83%	11.14%	7.45%	12.56%	17.88%
Free Cash Flow Margin	-6.41%	27.27%	0.99%	9.96%	13.61%	16.55%
EBITDA	4,379	23,590	12,267	10,568	19,551	20,106
EBITDA Margin	5.34%	25.09%	17.03%	14.48%	25.71%	26.82%
D&A For EBITDA	2,720	2,554	2,753	2,568	2,486	2,318
EBIT	1,659	21,036	9,514	8,000	17,065	17,788
EBIT Margin	2.02%	22.37%	13.21%	10.96%	22.44%	23.72%
Effective Tax Rate	59.21%	28.25%	18.07%	20.20%	31.23%	28.15%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.